# US 2024/0252562 A1 · Methods of heat inactivation of adenovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252562 A1
- Document ID: US20240252562A1
- Status: Published application
- Kind: A1
- Application number: 18/591,746
- Filed: 2024-02-29
- Published: 2024-08-01
- Earliest claimed: 2016-03-28
- Assignees: Ultragenyx Pharmaceutical Inc.
- Applicants: Ultragenyx Pharmaceutical Inc.
- Inventors: Christopher J. Morrison; James D. Maratt
- Web page: https://patentgrep.com/patent/US20240252562A1

## CPC

- A61K 35/761: Adenovirus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- C12N 2523/00: Culture process characterised by temperature
- C12N 2710/10361: Methods of inactivation or attenuation
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure generally relates to methods of protecting the genomic integrity and/or biological activity of AAV viral particles in a sample containing both AAV particles and helper virus particles during heat inactivation. The methods include heating, to a temperature greater than or equal to 45° C., a sample containing helper virus particles, AAV particles, and a buffer. The buffer includes a concentration of 10 mM or greater kosmotropic salts and/or a concentration of 10 mM or greater of divalent or trivalent cations.

## Claims

### Claim at position 1

1-55. (canceled)

### Claim 56

A method for manufacturing recombinant adeno-associated virus (rAAV) particles comprising:
a) producing a sample containing helper virus and rAAV particles by culturing mammalian or insect cells in a cell culture and providing the mammalian or insect cells with: (i) a plasmid that contains a rAAV genome, an AAV rep gene function and an AAV cap gene function; and (ii) helper virus; and
b) inactivating the helper virus in the sample by heating the sample to a temperature greater than or equal to 45° C. for between one minute and six hours in the presence of a buffer, wherein the buffer comprises a concentration of 10 mM or greater of divalent or trivalent cations, or a concentration of 10 mM or greater of kosmotropic salt.

### Claim 57 (depends on 56)

The method of claim 56, wherein the inactivating step comprises heating the sample to a temperature between 45° C. and 65° C.

### Claim 58 (depends on 56)

The method of claim 56, wherein the inactivating step comprises maintaining the temperature for a time period of between 10 and 180 minutes.

### Claim 59 (depends on 56)

The method of claim 56, wherein the rAAV particle comprises a genome of 3.0 kb of DNA to 5.2 kb of DNA.

### Claim 60 (depends on 56)

The method of claim 56, wherein the buffer further comprises:
a) a chaotropic salt; or
b) a polyol selected from the group comprising: glycerol, propylene glycol, and 1,6-hexanediol.

### Claim 61 (depends on 56)

The method of claim 56, wherein the buffer maintains a pH between 3.0 and 10.0 at temperatures between 4° C. and 70° C.

### Claim 62 (depends on 61)

The method of claim 61, wherein the buffer is a Tris buffer, a phosphate buffer, or a triazolamine buffer.

### Claim 63 (depends on 56)

The method of claim 56, wherein the buffer further comprises: 40 mM bis-tris propane, 20 mM HEPES, 20 mM citrate, 200 mM NaCI, and 0.001% (w/v) Pluronic F68.

### Claim 64 (depends on 56)

The method of claim 56, wherein the helper virus is an adenovirus.

### Claim 65 (depends on 64)

The method of claim 64, wherein the adenovirus is Ad5.

### Claim 66 (depends on 56)

The method of claim 56, wherein the concentration of divalent or trivalent cations is 25 mM to 500 mM.

### Claim 67 (depends on 56)

The method of claim 56, wherein the divalent or trivalent cations are selected from the group consisting of: Mg, Ca, Mn, Ni, Zn, Co, Sr, Cu, Cr, Fe, and Sc.

### Claim 68 (depends on 67)

The method of claim 67, wherein the divalent cations are selected from the group consisting of: Mg2+, Ca2+, Mn2+, Ni2+, Zn2+, Co2+, Sr2+, Cu2+ and Cr2+.

### Claim 69 (depends on 67)

The method of claim 67, wherein the trivalent cations are Sc3+.

### Claim 70 (depends on 56)

The method of claim 56, wherein the kosmotropic salt is selected from the group consisting of ammonium sulfate, ammonium acetate, sodium citrate, sodium acetate, sodium sulfate, potassium phosphate, and cesium chloride.

### Claim 71 (depends on 70)

The method of claim 70, wherein the concentration of the kosmotropic salt is 0.5 M to 0.6 M.

### Claim 72 (depends on 56)

A sample comprising rAAV particles and inactivated helper virus particles, wherein the sample is produced according to the method of claim 56.

### Claim 73 (depends on 56)

A sample comprising rAAV particles purified from a sample containing rAAV particles and inactivated helper virus particles produced according to the method of claim 56.

### Claim 74

A method for manufacturing rAAV particles comprising:
a) producing a sample containing helper virus and rAAV particles by culturing mammalian or insect cells in a cell culture and providing the mammalian or insect cells with: (i) a plasmid that contains a rAAV genome, an AAV rep gene function and an AAV cap gene function; and (ii) helper virus; and
b) inactivating the helper virus in the sample by heating the sample to a temperature greater than or equal to 45° C. for between one minute and six hours in the presence of a buffer, wherein the buffer comprises a concentration of 25 mM to 500 mM of divalent or trivalent cations, or a concentration of 0.5 M to 0.6 M of kosmotropic salt.

### Claim 75 (depends on 74)

A plurality of rAAV particles manufactured according to the method of claim 74.
